Screener
Alamar Biosciences ALMR Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Alamar Biosciences in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Alamar Biosciences’s 10-Q, filed May 8, 2026.
- Filed
- May 8, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-213424
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Maturities of short-term investments | — | 18,000 |
| Purchases of property and equipment | (600) | (554) |
| Capitalized software development costs | (178) | (428) |
| Net cash (used in) provided by investing activities | (778) | 17,018 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of convertible notes | 56,500 | — |
| Payment of third-party debt issuance costs | (324) | — |
| Proceeds from issuance of common stock upon exercise of stock options | 1,803 | 243 |
Item 1. Financial Statements
FAQ
- What is Alamar Biosciences's investing cash flow?
- Alamar Biosciences (ALMR) reported investing cash flow of -$778K in Q1 2026.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Alamar Biosciences's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude